This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Botulinum neurotoxin
From Proteopedia
(Difference between revisions)
(New page: <StructureSection load='3bta' size='340' side='right' caption='Clostridium botulinum neurotoxin type A with cofactor Zn+2 (grey) (PDB code 3bta).' scene=''> '''Botulinum neurotoxin'''...) |
|||
| Line 1: | Line 1: | ||
| - | |||
<StructureSection load='3bta' size='340' side='right' caption='Clostridium botulinum neurotoxin type A with cofactor Zn+2 (grey) (PDB code [[3bta]]).' scene=''> | <StructureSection load='3bta' size='340' side='right' caption='Clostridium botulinum neurotoxin type A with cofactor Zn+2 (grey) (PDB code [[3bta]]).' scene=''> | ||
| - | '''Botulinum neurotoxin''' (CBN) is produced by the bacterium ''Clostridium botulinum''. CBP contains a light and a heavy chains (LC and HC). CBP HC contains two modules: the N-terminal translocation domain and the C-terminal receptor-binding domain. CBP LC proteolyzes SNARE substrates which are essential for synaptic vescicle fusion and neurotransmitter release thus causing paralysis. CBP HC acts as a channel and as transmembrane chaperone enabling the passage of the LC into the cytosol. CBP type A is used by the cosmetics industry for smoothing wrinkles and is known commercially as Botox. For more details see [[Clostridium Botulinum Neurotoxin Type B]]. | + | '''Botulinum neurotoxin''' (CBN) is produced by the bacterium ''Clostridium botulinum''. CBP contains a light (residues 1-440) and a heavy (resides 441-875) chains (LC and HC). CBP HC contains two modules: the N-terminal translocation domain and the C-terminal receptor-binding domain (residues 876-1296). CBP LC proteolyzes SNARE substrates which are essential for synaptic vescicle fusion and neurotransmitter release thus causing paralysis. CBP HC acts as a channel and as transmembrane chaperone enabling the passage of the LC into the cytosol. CBP type A is used by the cosmetics industry for smoothing wrinkles and is known commercially as Botox. For more details see [[Clostridium Botulinum Neurotoxin Type B]]. |
| Line 18: | Line 17: | ||
{{#tree:id=OrganizedByTopic|openlevels=0| | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
| - | *'''Type A | + | *'''Type A ''' |
**[[1s0b]], [[3bta]], [[4ej5]] – CbCBN + Zn – ''Clostridium botulinum'' <br /> | **[[1s0b]], [[3bta]], [[4ej5]] – CbCBN + Zn – ''Clostridium botulinum'' <br /> | ||
| Line 25: | Line 24: | ||
**[[3v0a]], [[3v0b]] - CbCBN (mutant) + antibody + Type A progenitor toxin + Zn<br /> | **[[3v0a]], [[3v0b]] - CbCBN (mutant) + antibody + Type A progenitor toxin + Zn<br /> | ||
| - | *Type A Light Chain | + | *Type A Light Chain |
| - | **[[2g7k]], [[2g7p]], [[2g7q]], [[2imc]], [[3bwi]], [[3bok]], [[3qix]] - CbCBN LC + Zn<br /> | + | **[[2g7k]], [[2g7p]], [[2g7q]], [[2imc]], [[3bwi]], [[3bok]], [[3qix]], [[2ise]], [[2isg]], [[2ish]] - CbCBN LC + Zn<br /> |
**[[3bok]] - CbCBN LC <br /> | **[[3bok]] - CbCBN LC <br /> | ||
**[[1e1h]], [[1xtf]], [[4kuf]] - CbCBN LC (mutant) + Zn<br /> | **[[1e1h]], [[1xtf]], [[4kuf]] - CbCBN LC (mutant) + Zn<br /> | ||
**[[3dse]] – CbCBN LC (mutant) + Zn + Ni<br /> | **[[3dse]] – CbCBN LC (mutant) + Zn + Ni<br /> | ||
**[[1xtg]] - CbCBN LC (mutant) + synaptosomal-associated protein 25 + Zn<br /> | **[[1xtg]] - CbCBN LC (mutant) + synaptosomal-associated protein 25 + Zn<br /> | ||
| - | **[[3dda]] - CbCBN LC + synaptosomal-associated protein 25 peptide + Zn<br /> | + | **[[3dda]], [[3ddb]] - CbCBN LC + synaptosomal-associated protein 25 peptide + Zn<br /> |
**[[3zur]], [[3zus]] - CbCBN LC/synaptosomal-associated protein 25 translocation domain<br /> | **[[3zur]], [[3zus]] - CbCBN LC/synaptosomal-associated protein 25 translocation domain<br /> | ||
| - | **[[2g7n]], [[2ilp]], [[2imb]], [[3qiy]], [[3qiz]], [[3qj0]], [[4hev]] – CbCBN LC + inhibitor + Zn<br /> | + | **[[2g7n]], [[2ilp]], [[2imb]], [[3qiy]], [[3qiz]], [[3qj0]], [[4hev]], [[2ima]] – CbCBN LC + inhibitor + Zn<br /> |
| - | **[[3c88]], [[3c89]], [[3c8a]], [[3c8b]], [[3boo]], [[3qw5]], [[3qw6]], [[3qw7]], [[3qw8]] – CbCBN LC + inhibitor peptide + Zn<br /> | + | **[[3c88]], [[3c89]], [[3c8a]], [[3c8b]], [[3boo]], [[3qw5]], [[3qw6]], [[3qw7]], [[3qw8]], [[3nf3]] – CbCBN LC + inhibitor peptide + Zn<br /> |
**[[4ks6]], [[4ktx]] - CbCBN LC (mutant) + inhibitor peptide + Zn<br /> | **[[4ks6]], [[4ktx]] - CbCBN LC (mutant) + inhibitor peptide + Zn<br /> | ||
**[[3ds9]] – CbCBN LC (mutant) + inhibitor peptide + Zn + Ni<br /> | **[[3ds9]] – CbCBN LC (mutant) + inhibitor peptide + Zn + Ni<br /> | ||
| Line 41: | Line 40: | ||
**[[3k3q]] - CbCBN LC + antibody + Zn<br /> | **[[3k3q]] - CbCBN LC + antibody + Zn<br /> | ||
| - | *Type A receptor-binding domain | + | *Type A receptor-binding domain |
**[[2vua]], [[3fuo]] – CbPBN <br /> | **[[2vua]], [[3fuo]] – CbPBN <br /> | ||
| Line 48: | Line 47: | ||
**[[4jra]] – CbCBN + synaptic vesicle glycoprotein 2C<br /> | **[[4jra]] – CbCBN + synaptic vesicle glycoprotein 2C<br /> | ||
| - | *Type A Light+Heavy Chains | + | *Type A Light+Heavy Chains |
**[[2w2d]] - CbCBN LC+HC + Zn<br /> | **[[2w2d]] - CbCBN LC+HC + Zn<br /> | ||
| Line 54: | Line 53: | ||
*'''Type B''' | *'''Type B''' | ||
| - | **[[1s0b]], [[1s0c]], [[1s0d]], [[1s0e]], [[1s0f]], [[1s0g]], [[1epw]] – CbCBN + Zn<br /> | + | **[[1s0b]], [[1s0c]], [[1s0d]], [[1s0e]], [[1s0f]], [[1s0g]], [[1epw]], [[1f82]] – CbCBN + Zn<br /> |
**[[2np0]] – CbCBN + synaptotagmin-2 + Zn<br /> | **[[2np0]] – CbCBN + synaptotagmin-2 + Zn<br /> | ||
**[[1g9a]], [[1g9b]], [[1g9c]], [[1g9d]] – CbCBN + inhibitor + Zn<br /> | **[[1g9a]], [[1g9b]], [[1g9c]], [[1g9d]] – CbCBN + inhibitor + Zn<br /> | ||
**[[1i1e]] – CbCBN + doxorubicin + Zn<br /> | **[[1i1e]] – CbCBN + doxorubicin + Zn<br /> | ||
**[[1f31]] – CbPBN + trisaccharide + Zn<br /> | **[[1f31]] – CbPBN + trisaccharide + Zn<br /> | ||
| + | |||
| + | **[[1z0h]] – CbCBN C terminal<br /> | ||
| + | |||
| + | *Type B Light Chain | ||
| + | |||
| + | **[[2etf]], [[3zuq]] - CbCBN LC + Zn<br /> | ||
| + | |||
| + | *Type B Light+Heavy Chains | ||
| + | |||
| + | **[[2xhl]] - CbCBN LC+HC + Zn<br /> | ||
| + | |||
| + | *Type B receptor-binding domain | ||
| + | |||
| + | **[[2nm1]], [[4kbb]] - CbCBN + synaptotagmin-2<br /> | ||
| + | |||
| + | *Type C Light Chain | ||
| + | |||
| + | **[[2qn0]] - CbCBN LC + Zn<br /> | ||
| + | **[[3deb]] - CbCBN LC (mutant)<br /> | ||
| + | |||
| + | *Type C receptor-binding domain | ||
| + | |||
| + | **[[3n7k]], [[3r4s]], [[3r4u]] - CbCBN <br /> | ||
| + | |||
| + | *Type D Light Chain | ||
| + | |||
| + | **[[2fpq]] - CbCBN LC + Zn<br /> | ||
| + | |||
| + | *Type D receptor-binding domain | ||
| + | |||
| + | **[[3n7j]], [[3obr]], [[3ogg]] - CbCBN <br /> | ||
| + | **[[3rmx]], [[3rmy]] – CbCBN (mutant) <br /> | ||
| + | **[[3obt]] - CbCBN + acetylneuraminic acid<br /> | ||
| + | |||
| + | *Type E | ||
| + | |||
| + | **[[1t3a]], [[3ffz]] – CbCBN + Zn<br /> | ||
| + | **[[1t3c]], [[1zkw]], [[1zkx]], [[1zl5]], [[1zl6]], [[1zn3]] – CbCBN (mutant) + Zn<br /> | ||
| + | |||
| + | *Type F Light Chain | ||
| + | |||
| + | **[[2a8a]], [[2a97]] - CbCBN LC + Zn<br /> | ||
| + | **[[3fie]], [[3fii]] - CbCBN LC + Zn + synaptobrevin-2<br /> | ||
| + | |||
| + | *Type F receptor-binding domain | ||
| + | |||
| + | **[[3rsj]] - CbCBN <br /> | ||
| + | |||
| + | *Type G Light Chain | ||
| + | |||
| + | **[[1zb7]] - CbCBN LC + Zn<br /> | ||
| + | |||
| + | *Type G receptor-binding domain | ||
| + | |||
| + | **[[2vxr]], [[3mpp]] - CbCBN <br /> | ||
}} | }} | ||
[[Category: Topic Page]] | [[Category: Topic Page]] | ||
Revision as of 07:45, 9 March 2015
| |||||||||||
3D structures of botulinum neurotoxin
Updated on 09-March-2015
